食管癌的立体适形放疗和同步化疗  

Stereotactic radiotherapy and chemotherapy for esophageal carcinoma

作　　者：王洪林[1] 陶莉[1] 王利[2] 魏子祥[2] 

机构地区：[1]复旦大学附属上海市第五人民医院,上海200240 [2]安徽省淮南煤矿肿瘤医院

出　　处：《实用肿瘤学杂志》2004年第3期181-183,共3页Practical Oncology Journal

摘　　要：目的 应用立体适形放射治疗技术并同步化学治疗食管癌,评价疗效和并发症。方法52例食管癌给予立体适形放射治疗和同步化疗。放疗:2-2.2GY/次/天,5次/周,共计35次:5-8个共面适形固定野,总剂量70-76GY。化疗:顺氨氯铂20mg,5-氟脲嘧啶500 mg,每周一次,放疗开始即同步使用化疗,化疗在放疗前进行。结果治疗后1月-6月复查食管X片和CT,肿瘤缩小50％以上者92.31％(48/52);1年、3年和5年生存率分别为78.85％(41/52);41.46％(17/41);26.92％(7/26)。结论立体适形放射治疗和同步化学治疗食管癌,宁效较好,并发症少,是不能手术患者的较好的一种治疗方式。Objective To evaluate the treatment efficacy and complications of stererotactic radiotherapy and chemotherapy for esophageal carcinoma. Methods Fifty-two patients with csophageal carcinoma received stereotactic radiotherapy 2.0-2.2 GY/fraction every day, five days per week, and were added up to 35 fractions . They were given 5-8 coplanar stationary beams stereotactic radiotherapy with total dose of 70 - 76 GY. The chemotherapy consisting of DDP 20mg plus 5 - FU 500mg for 1 day, was given prior to the radiatheapy. Results The check of the patients' X-ray films and CT images at 1 - 6 month after the treatment showed that the rate atleast 50% tumordeenease was 92.31% (48/52). One, three and five year survival rates were 78.85%(41/52), 41.46(17/41) and 26.92%(7/26), respectively. Conclusion The stereotactic radiotherapy and chemotherapy for esophageal carcinoma can increase efficacy and decrease complications and be the better therapy for the un-operation patients.

关 键 词：食管癌 立体适形放疗 同步化疗 评价 疗效 

分 类 号：R735.1[医药卫生—肿瘤]